DAFTAR PUSTAKA

Acharya SP, Pradhan B, dan Marhatta MN, 2007. Application of "the Sequential Organ Failure Assessment (SOFA) Score" in Predicting Outcome in ICU Patients with SIRS, *Kathmandu University Medical Journal*, 5(4), Issue 20, p: 475-83.

Almansa R, Wain J, Tamayo E, Andaluz-Ojeda D, Martin-Loeches I, Ramirez P, *et al.*, 2013. Immunological Monitoring to Prevent and Treat Sepsis, *Critical Care*, 17(109), p: 1-3.

Anevlavis S, Kaltsas K, dan Bouros D, 2014, Procalcitonin as a Marker of Bacterial Infection in Elderly Patients, *Pneumon*, 27(1), p: 1-15.

Annane D, Bellissant E, Cavaillon JM, 2005. Septic Shock, *Lancet*, 365, p: 63-78.

Artero A, Zaragoza R, Nogueira JM, 2012. Epidemiology of Severe Sepsis and Septic Shock in *Severe Sepsis and Septic Shock - Understanding a Serious Killer*, Editor : Fernandez R, InTech, Europe, p: 3-24.

Bantel H dan Schulze-Osthoff K, 2009. Cell Death in Sepsis: A Matter of How, When, and Where, *Critical Care*, 13(173), p: 1-3.

Behnes M, Bertsch T, Lepiorz D, Lang S, Trinkmann F, *et al*., 2014. Diagnostic and Prognostic Utility of Soluble CD 14 Subtype (Presepsin) for Severe Sepsis and Septic Shock during the First Week of Intensive Care Treatment, *Critical Care*, 18(507), p: 1-13.

Behnes M, Bertsch T, Lepiorz D, Lang S, Trinkmann F, *et al*., 2014. Diagnostic and Predictive Value of Presepsin (sCD14-ST) in the Time Course of Sepsis, Poster: *Institute for Clinical Chemistry, Laboratory and Transfusion Medicine, Nuremberg Hospital, Germany*, p:1.

Camacho Z dan Losa J, 2014. Biomarkers for sepsis, *BioMed Research International*, 2014, p: 1-6.

Castelli GP, Pognani C, Meisner M, Stuani A, Bellomi D dan Sgarbi L, 2004. Procalcitonin and CRP during Systemic Inflammatory Response Syndrome, Sepsis and Organ Dysfunction, *Critical Care*, 8, p: R234-R242.

Cawcutt KA dan Peters SG, 2014. Severe Sepsis and Septic Shock: Clinical Overview and Update on Management, *Mayo Clin Proc*., 89(11), p: 1572-8.

Cohen J, 2002. The Immunopathogenesis of Sepsis, *Nature*, 420, p: 885-90.

Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, *et al.*, 2013. Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2012, *Crit Care Med*, 41, p: 580–637.

Dunne WM, 2015, Laboratory Diagnosis of Sepsis? No SIRS, Not Just Yet, *Journal of Clinical Microbiology*, 53(8), p: 2404-9.

Faix JD, 2013. Biomarkers of Sepsis, *Crit Rev Clin Lab Sci*, 50(1), p: 23–36.

Ferreira FL, Bota DP, Bross A, Melot C, dan Vincent JL, 2001, Serial Evaluation of the SOFA Score to Predict Outcome in Critically Ill Patients, *JAMA*, 286, p: 1754-8.

Gattas DJ dan Cook DJ, 2003. Procalcitonin as a Diagnostic Test for Sepsis: Health Technology Assessment in the ICU, *Journal of Crit Care*, 18(1), p: 52-58.

Gottesman T, Yossepowitch O, Schwartz O, Rokney A, Soroksky A dan Dan M, 2012. Severe Sepsis from Community-Associated Methicillin-Resistant Staphylococcus aureus Possibly due to Implantable Cardioverter Defibrillator, *Israel Medical Association Journal*, 14, p: 774-775.

Hendrianingtyas, Banundari RH, Indranila KS, dan Budiwiyono I, 2014, *Prokalsitonin, CRP dan Presepsin di SIRS*, Indonesian Journal of Clinical Phatology and Medical Laboratory, 20(3), p: 184-91.

Hofer N, Müller W dan Resch B, 2013. The Role of C-Reactive Protein in the Diagnosis of Neonatal Sepsis, *Intech*, p: 45-58.

Hotchkiss RS, Tinsley KW, Swanson PE, Grayson MH, Osborne DF dan Wagner TH, 2002. Depletion of Dendritic Cells, But Not Macrophages, in Patients with Sepsis, *J Immunol.*, 168, p: 2493-2500.

Jones AE, Trzeciak S, dan Kline JA, 2009. The Sequential Organ Failure Assessment Score for Predicting Outcome in Patients with Severe Sepsis and Evidence of Hypoperfusion at the Time of Emergency Department Presentation, *Crit Care Med*, 37(5), p:1649-54.

Kato H, Izumi M, dan Kaneko T, 2015. Comparison of Presepsin and Procalcitonin Levels in the Diagnosis of Non-bacteremic and Bacteremic Infections, Open Forum Infectious Diseases, 2, p: 71-536.

Kaplan LJ, 2015. Systemic Inflammatory Response Syndrome, *Medscape Reference*, p: 1-3.

Khwannimit B dan Bhurayanontachai R, 2009. The Epidemiology of, and Risk Factors for, Mortality from Severe Sepsis and Septic Shock in a Tertiary-care University Hospital Setting, *Epidemiol*. *Infect*., 137, p: 1333-41.

Kroncke K, Fehsel K dan Kolb-Bachofen V, 1998. Inducible Nitric Oxide Synthase in Human Diseases, *Clin Exp Immunol.*, 113, p: 147-56.

Kujawa K dan Saleh F, 2007. Sepsis: A Review of Pathophysiology and Management, *McMaster University Medical Journal*, 4(1), p: 3-8.

Kweon OJ, Choi J, Park SK, dan Park AJ, 2014. Usefulness of Presepsin (sCD14 Subtype) Measurements as a New Marker for The Diagnosis and Prediction of Disease Severity of Sepsis in the Korean Population, *Journal of Critical Care*, 29, p: 965–70.

Lever A dan Mackenzie I, 2007. Sepsis: Definition, Epidemiology, and Diagnosis, *BMJ*, 335, p: 879-83.

Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, *et al.*, 2003. **S**CCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference, *Intensive Care Med*, 29, p: 530–38.

Lien E, Aukrust P, Sundan A, Muller F, Froland SS, dan Espevik T, 1998, Elevated Levels of Serum-Soluble CD14 in Human Immunodeficiency Virus Type 1 (HIV-1) Infection: Correlation to Disease Progression and Clinical Events, *Blood*, 92(6), p: 2084-92.

Liu B, Chen YX, Yin Q, Zhao Y, Li C, 2013. Diagnostic Value and Prognostic Evaluation of Presepsin for Sepsis in An Emergency Department, *Critical Care*, 17(R244), p: 1-12.

Makarova P, Galstyan G, Krechetova A, Gemdjian E, *et al*., 2014. Usefulness Of Presepsin (Psp) For Assessment Of Sepsis In Leukopenic Patients (Pts), ESICM LIVES 2014 27th Annual Congress, *Intensive Care Med*, 40 (Suppl 1), p: 0055.

Maravic-Stojkovic V, Lausevic-Vuk L, Jovic M, Filipovic M, Bojic Milinovic T, *et al*., 2014. Levels of Presepsin and Midregion-Proadrenomedullin in Septic Patients with End-Stage Renal Disease after Cardiovascular Surgery: 1-Year Follow Up Study, *J Clin Exp Cardiolog*, 5, p: 307(1-6).

Martin GS, Mannino DM, Eaton S, Moss M, 2003. The Epidemiology of Sepsis in the United States from 1979 through 2000, *N Engl J Med*., 348, p: 1546-54.

Masson S, Caironi P, Spanuth E, Thomae R, Panigada M, *et al*., 2014, Presepsin (Soluble CD14 Subtype) and Procalcitonin Levels for Mortality Prediction in Sepsis: Data from The Albumin Italian Outcome Sepsis Trial, *Critical Care*, 18(R6), p: 1-9.

Maurice M, Nafea D, El Sawy M, Soelam R, dan Youssef S, 2014. Usefulness of Presepsin (Soluble CD14 Subtype) as a Diagnostic Marker of Sepsis in Egyptian Patients with Acute Myeloid Leukemia, *American Journal of Molecular Biology*, 4, p: 169-76.

Meissner M, Tschaikovsky K, Palmaers T, dan Schmidt J, 1999. Comparison of Procalcitonin (PCT) and C-reactive Protein (CRP) Plasma Concentrations at Different SOFA Scores during the Course of Sepsis and MODS, *Critical Care*, 3, p: 45-50.

Mossie A, 2013. Pathophysiology Of Sepsis, *World Journal of Medicine and Medical Science*, 1(8), p: 159-168.

Munger JA, 2015. Determination of Soluble CD14 Molecular Weight Variants in Human Plasma, *UVM College of Arts and Sciences College Honors Theses*. Paper 19.

Nagata T, Yasuda Y, Ando M, Abe T, Katsuno T, Kato S, *et al.*, 2015. Clinical Impact of Kidney Function on Presepsin Levels. *PLoS ONE*, 10(6), p: 1-10.

Nair R, Bhandary NM, dan D'Souza AD, 2016, Initial Sequential Organ Failure Assessment Score versus Simplified Acute Physiology Score to Analyze Multiple Organ Dysfunction in Infectious Diseases in Intensive Care Unit, *Indian J Crit Care Med*., 20, p:210-5.

Nakamura Y, Ishikura H, Nishida T, Kawano Y, Yuge R, *et al*., 2014. Usefulness Of Presepsin In The Diagnosis of Sepsis In Patients With or Without Acute Kidney Injury, *BMC Anesthesiology*, 14(88), p: 1-7.

Nduka OO dan Parrillo JE, 2009. The Pathophysiology of Septic Shock, *Crit Care Clin.*, 25, p: 677–702.

Nesseler N, Launey Y, Aninat C, Morel F, Malledant Y, dan Seguin P, 2012. Clinical Review: The Liver in Sepsis, *Critical Care*, 16(235), p: 1-8.

Nishida T, Ishikura H, Murai A, Irie Y, Yuge R, Kamitani R, Endo S, *et al*., 2012, Assessment of the Usefulness of Presepsin (Soluble CD14 Subtype) in Septic Patients, *Critical Care*, 16(1), p:32.

Oberholzer C, Oberholzer A, Clare-Salzler M, Moldawer LL, 2001. Apoptosis in Sepsis: A New Target for Therapeutic Exploration, *Faseb J.*, 15, p: 879–892.

Pathfast, 2013. Presepsis Manual, Mitsubishi Chemical, Japan, p: 1-6.

Pierrakos C dan Vincent J, 2010. Sepsis Biomarkers: a Review, *Crit Care*, 14(R15), p: 1-18.

Popov D, Plyushch M, Ovseenko S, Abramyan M, Podshchekoldina O, et *al.*, 2015. Prognostic value of sCD14-ST (presepsin) in Cardiac Surgery, *Kardiochirurgia i Torakochirurgia Polska*, 12(1), p: 30-6.

Póvoa P, 2002. C-Reactive Protein: A Valuable Marker of Sepsis, *Intensive Care Med.*, 28, p: 235-43.

Pradipta IS, Sandiana AT, Halimah E, Diantini A, Lestari K, Abdulah R, 2013. Microbial and Resistance Profile in Isolate from Adult Sepsis Patients: An Observational Study at an Indonesian Private Hospital during 2009-2012, *Int. J. Pharm. Sci. Rev. Res.*, 19(2), p: 24-29.

Pugin J, Meisner M, Leon A, Gendrel D, Lopez AF, 2008. Guide for the Clinical Use of Procalcitonin (PCT) In Diagnosis and Monitoring of Sepsis, 7th Ed, B·R·A·H·M·S Aktiengesellschaft, p: 1-24.

Ramana KV, Pinnelli VB, Kandi S, Asha G, Jayashankar CA, Bhanuprakash, *et al.*, 2014. Presepsin: A Novel and Potential Diagnostic Biomarker for Sepsis, *American Journal of Medical and Biological Research*, 2(4), p: 97-100.

Nair R, Bhandary NM, dan D'Souza AD, 2016. Initial Sequential Organ Failure Assessment score versus Simplified Acute Physiology score to analyze Multiple Organ Dysfunction in Infectious Diseases in Intensive Care Unit, *Indian J Crit Care Med.*, 20, p: 210-5.

Russel JA, 2006. Management of Sepsis, *N Engl J Med.*, 355, p: 1699-713.

Sato M, Takahashi G, Shibata S, Onodera M, Suzuki Y, Inoue Y, *et al.*, 2015. Clinical Performance of a New Soluble CD14-Subtype Immunochromatographic Test for Whole Blood Compared with Chemiluminescent Enzyme Immunoassay: Use of Quantitative Soluble CD14-Subtype Immunochromatographic Tests for the Diagnosis of Sepsis, *PLoS ONE*, 10(12), p: 1-10.

Sato R, Suzuki Y, Sato M, Takahashi G, Kojika M, Inoue Y, Endo S, 2013. Serum levels of presepsin reflects the APACHE II and SOFA scores in patients with sepsis, *Critical Care*, 17(Suppl 2), p: 37.

Schuetz P dan Mueller B, 2014. The Role of Immune and Metabolic Biomarkers for Improved Management of Sepsis Patients, *Expert Rev. Clin. Immunol.*, early online, p: 1-8.

Shozushima T, Suzuki Y, Masuda T, Takahashi G, Endo S, 2011. Usefulness of Presepsin (sCD14-ST) Measurements as a Marker for the Diagnosis and Severity of Sepsis in Systemic Inflammatory Response Syndrome, *Critical Care*, 15(Suppl 1), p: 414.

Silva E, Passos RDH, Ferri MB, Figueiredo LFP, 2008. Sepsis: from Bench to Bedside, *Clinics*, 63(1), p: 109-20.

Soreng K dan Levy HR, 2011. Procalcitonin: an Emerging Biomarker of Bacterial Sepsis, *Clinical Microbiology Newsletter*, 33(22), p: 171-8.

Soultati A dan Dourakis SP, 2005. Liver Dysfunction In The Intensive Care Unit, *Annals of Gastroenterolog*, 18(1), p:35-45.

Spanuth E, Ebelt H, Ivandic B dan Werdan K, 2011. Diagnostic and Prognostic Value of Presepsin (Soluble CD14 Subtype) in Emergency Patients with Early Sepsis Using The New Assay PATHFAST, *21st International Congress of Clinical Chemistry and Laboratory Medicine*, p: 1-2.

Sriskandan S dan Altmann DM, 2008. The Immunology of Sepsis, *J Pathol.*, 214, p: 211–223.

Stubljar D, Kopitar AN, Groselj-Grenc M, Suhadolc K, Fabjan T, dan Skvarc M, 2015, Diagnostic Accuracy of Presepsin (sCD14-ST) for Prediction of Bacterial Infection in Cerebrospinal Fluid Samples from Children with Suspected Bacterial Meningitis or Ventriculitis, *Journal of Clinical Microbiology*, 53(4), 1239-44.

Tupchong K, Koyfman A, Foran M, 2014. Sepsis, Severe Sepsis, and Septic Shock: A Review of the Literature, *Afr J Emerg Med, hosting by elsevier*, p: 1-9.

Tutak E, Ozer AB, Demirel I, dan Bayar MK, 2013. The Relationship Between Serum Bilirubin Level With Interleukin-6, Interleukin-10 And Mortality Scores In Patients With Sepsis, *NJCP*, 17(4), p: 517-22.

Ulla M, Pizzolato E, Lucchiari M, Loiacono M, Soardo F, *et al.*, 2013. Diagnostic and prognostic value of presepsin in the management of sepsis in the emergency department: a multicenter prospective study, *Critical Care*, 17(R168), p: 1-8.

Vincent JL, Moreno R, Takala J, Willatts S, Mendonca D, *et al*., 1996. The SOFA (Sepsis-related Organ Failure Assessment) score to describe Organ Dysfunction/Failure, *Critical Care*, 22, p: 707-10.

Vincent JL, Moreno R, Takala J, Willatts S, Mendonca D, *et al*., 1998. Use of the SOFA Score to Assess the Incidence of Organ Dysfunction/Failure in Intensive Care Units: Results of a Multicenter, Prospective Study, *Crit Care Med*., 26, p: 1793-800.

Vincent JL, 2008. Clinical Sepsis and Septic Shock - Definition, Diagnosis and Management Principles, *Langenbecks Arch Surg*, 393, p: 817–24.

Vincent JL, 2009. Definition of Sepsis and Non-infectious SIRS in *Sepsis and Non-infectious Systemic Inflammation*, Editor : Cavaillon JM dan Adrie C, Wiley-Vch Verlag & Co., Weinheim, p: 3-12.

Vincent JL, Rello J, Marshal J, 2009. International Study of the Prevalence and Outcomes of Infection in Intensive Care Units, JAMA, 302, p: 2323-9.

Vosylius S, Sipylaite J, dan Ivaskevicius J, 2004. Sequential Organ Failure Assessment Score as the Determinant of Outcome for Patients with Severe Sepsis, *Croatian Medical Journal*, 45(6), p: 715-20.

Wu J, Hu L, Zhang G, Wu F, dan He T, 2015. Accuracy of Presepsin in Sepsis Diagnosis: A Systematic Review and Meta-Analysis, *PLoS ONE*, 10(7), p: 1-15.

Yaegashi Y, Shirakawa K, Sato N, Suzuki Y, Kojima M, *et al*., 2005. Evaluation of a Newly Identified Soluble CD14 Subtype as a Marker for Sepsis, J Infect. Chemother., 11(5), p: 234-8.

Xie L, 2012. New Biomarkers for Sepsis in *Sepsis – An Ongoing and Significant Challenge*, Editor : Azevedo L, Intech, Europe, p: 171-86.

Zhai R, Sheu CC, Su L, Gong MN, Tejera P, Chen F, *et al*., 2009. Serum Bilirubin Levels on ICU Admission are Associated with ARDS Development and Mortality in Sepsis, *Thorax*; 64(9): p: 784-90.

Zhao H, 2011. Improved Methods of Sepsis Case Identification and the Effects of Treatment with Low Dose Steroids: A Dissertation, University of Massachusetts Medical School, *GSBS Dissertations and Theses*, Paper 529.

Zou Q, Wen W, Zhang X, 2014. Presepsin as a Novel Sepsis Biomarker, *World J Emerg Med*, 5(1), p: 16-9.